Ibrutinib-Venetoclax Improves PFS in R/R Mantle Cell Lymphoma

(MedPage Today) -- SAN DIEGO -- Patients with relapsed/refractory mantle cell lymphoma (MCL) lived significantly longer without disease progression with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta), according to a randomized...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news